Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 5:21 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 1,039 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: LCC Clear all
Recruiting Phase 2 Interventional

Y-90 Treatment Response Using Transarterial Radioembolization

NCT07145801
View directory record Official record
Conditions
HCC, Hepatocellular Carcinoma, Liver Cancer, Hepatic Neoplasm, Primary Liver Cancer, Liver Neoplasm
Interventions
Lumason, Sonazoid
Diagnostic Test
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 21, 2026, 5:21 PM EDT
Completed Phase 1 Interventional

Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)

NCT01183663
View directory record Official record
Conditions
Advanced Cancers
Interventions
Lenalidomide, Bevacizumab, Sorafenib, Temsirolimus, Oxaliplatin, Leucovorin, 5-fluorouracil
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 3, 2016 · Synced Oct 21, 2026, 5:21 PM EDT
Completed Phase 2 Interventional Results available

Chemoembolization Versus Radioembolization in Treating Patients With Liver Cancer That Cannot Be Treated With Radiofrequency Ablation Or Surgery

NCT00956930
View directory record Official record
Conditions
Liver Cancer
Interventions
yttrium Y 90 glass microspheres, Doxorubicin
Radiation · Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 120 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 21, 2022 · Synced Oct 21, 2026, 5:21 PM EDT
Not listed Not applicable Interventional

Surefire Institutional DEB-TACE

NCT03211598
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
TACE with Surefire
Procedure
Lead sponsor
Alexander Kim
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jan 22, 2020 · Synced Oct 21, 2026, 5:21 PM EDT
Not listed No phase listed Observational

The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)

NCT03896958
View directory record Official record
Conditions
Cancer, All Types, Cancer of Liver, Cancer of Stomach, Cancer of Head and Neck, Cancer of Rectum, Cancer of Kidney, Cancer of Esophagus, Cancer of Colon, Cancer Skin, Cancer of Cervix, Cancer, Metastatic, Cancer of Larynx, Cancer of Neck, Cancer of Lung, Cancer of Brain and Nervous System, Cancer of Vulva, Disseminated, Cancer of Pancreas, Sarcoma, GIST, Small-cell Lung Cancer, Adenocarcinoma Lung, Cancer of Prostate, Cancer, Advanced, Adrenal Cancer, Testicular Cancer, Uterine Cancer, Bronchoalveolar Cell Lung Cancer, Cancer Unknown Primary, Glioblastoma Multiforme, Oligodendroglioma, Breast Cancer, Renal Cell Carcinoma, Hepatocellular Carcinoma, Cholangiocarcinoma, Squamous Cell Carcinoma, Transitional Cell Carcinoma, Cancer, Other, Cancer, Anal, Melanoma, Cancer, Bile Duct, Cancer, Bladder, Cancer Cords Vocal, Cancers Cell Neuroendocrine, Cancer Differentiated Poorly, Cancer, Anaplastic Thyroid
Interventions
Not listed
Lead sponsor
SpeciCare
Industry
Eligibility
1 Month to 99 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Gainesville, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 4, 2020 · Synced Oct 21, 2026, 5:21 PM EDT
Completed Not applicable Interventional

Body Warming in Improving Blood Flow and Oxygen Delivery to Tumors in Patients With Cancer

NCT01896778
View directory record Official record
Conditions
Adult Liver Carcinoma, Breast Carcinoma, Colon Carcinoma, Kidney Neoplasm, Lung Carcinoma, Malignant Head and Neck Neoplasm, Malignant Neoplasm, Melanoma, Ovarian Neoplasm, Soft Tissue Sarcoma
Interventions
Hyperthermia Treatment, Laboratory Biomarker Analysis
Procedure · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jul 25, 2022 · Synced Oct 21, 2026, 5:21 PM EDT
Recruiting Phase 1 Interventional

A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

NCT06066138
View directory record Official record
Conditions
Locally Advanced Alveolar Soft Part Sarcoma, Metastatic Alveolar Soft Part Sarcoma, Locally Advanced Non Small Cell Lung Cancer, Metastatic Non Small Cell Lung Cancer, Locally Advanced Small Cell Lung Cancer, Metastatic Small Cell Lung Cancer, Locally Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma, Locally Advanced Melanoma, Metastatic Melanoma
Interventions
Atezolizumab
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 21, 2026, 5:21 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002)

NCT03713593
View directory record Official record
Conditions
Carcinoma, Hepatocellular
Interventions
lenvatinib, pembrolizumab, saline placebo
Drug · Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
794 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
21
States / cities
Tucson, Arizona • Duarte, California • La Jolla, California + 17 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 21, 2026, 5:21 PM EDT
Terminated Phase 2 Interventional Results available

Pravastatin Intervention to Delay Hepatocellular Carcinoma Recurrence

NCT03219372
View directory record Official record
Conditions
Hepatocellular Carcinoma, Liver Cirrhoses
Interventions
Pravastatin Pill, Placebo Oral Tablet
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 22, 2021 · Synced Oct 21, 2026, 5:21 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Study on Safety and Efficacy of NMS-01940153E in Adult Patients With Unresectable Hepatocellular Carcinoma (HCC) Previously Treated With Systemic Therapy

NCT05630937
View directory record Official record
Conditions
Unresectable Hepatocellular Carcinoma (HCC)
Interventions
NMS-01940153E
Drug
Lead sponsor
Nerviano Medical Sciences
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
2
States / cities
Orange, California • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 19, 2025 · Synced Oct 21, 2026, 5:21 PM EDT
Terminated No phase listed Observational

Prospective Tumor Response Evaluation

NCT02787954
View directory record Official record
Conditions
Hepatocellular Cancer, Metastatic Liver Cancer
Interventions
TACE, Y-90, MWA, IRE
Procedure
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 18, 2018 · Synced Oct 21, 2026, 5:21 PM EDT
Terminated Not applicable Interventional Results available

Sulfur Colloid SPECT/CT in Measuring Liver Function in Patients With Primary or Metastatic Liver Cancer Undergoing Radiation Therapy or Surgery

NCT02881554
View directory record Official record
Conditions
Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma, Stage IV Liver Cancer, Stage IVA Liver Cancer, Stage IVB Liver Cancer, Vascular Thrombosis
Interventions
Computed Tomography, Single Photon Emission Computed Tomography, Technetium Tc-99m Sulfur Colloid
Procedure · Drug
Lead sponsor
University of Washington
Other
Eligibility
19 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
2
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Oct 21, 2026, 5:21 PM EDT
Terminated Phase 1Phase 2 Interventional

Study of GNS561 in Patients With Liver Cancer

NCT03316222
View directory record Official record
Conditions
Hepatocellular Carcinoma, Cholangiocarcinoma, Intrahepatic
Interventions
GNS561
Drug
Lead sponsor
Genoscience Pharma
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 2, 2022 · Synced Oct 21, 2026, 5:21 PM EDT
Completed Phase 1 Interventional

hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse

NCT02960594
View directory record Official record
Conditions
Breast Cancer, Lung Cancer, Pancreatic Cancer, Head and Neck Cancer, Ovarian Cancer, ColoRectal Cancer, Gastric Cancer, Esophageal Cancer, HepatoCellular Carcinoma
Interventions
INO-1400, INO-9012, INO-1401
Biological
Lead sponsor
Inovio Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
6
States / cities
Detroit, Michigan • Rochester, Minnesota • Chapel Hill, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2018 · Synced Oct 21, 2026, 5:21 PM EDT
Active, not recruiting Phase 1 Interventional

IRX-2, Cyclophosphamide, and Nivolumab in Treating Patients With Recurrent or Metastatic and Refractory Liver Cancer

NCT03655002
View directory record Official record
Conditions
Recurrent Hepatocellular Carcinoma, Refractory Liver Carcinoma, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IVA Hepatocellular Carcinoma AJCC v8, Stage IVB Hepatocellular Carcinoma AJCC v8
Interventions
Cyclophosphamide, Cytokine-based Biologic Agent IRX-2, Nivolumab
Drug · Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
3
States / cities
Scottsdale, Arizona • Duarte, California • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 21, 2026, 5:21 PM EDT
Completed Phase 1 Interventional

MRI With Gadoxetate Disodium in Measuring Tumors in Patients With Liver Cancer

NCT02578602
View directory record Official record
Conditions
Adult Hepatocellular Carcinoma, Advanced Adult Hepatocellular Carcinoma, BCLC Stage 0 Adult Hepatocellular Carcinoma, BCLC Stage A Adult Hepatocellular Carcinoma, BCLC Stage B Adult Hepatocellular Carcinoma, BCLC Stage C Adult Hepatocellular Carcinoma, BCLC Stage D Adult Hepatocellular Carcinoma, Localized Non-Resectable Adult Liver Carcinoma, Localized Resectable Adult Liver Carcinoma
Interventions
Gadoxetate Disodium, Magnetic Resonance Imaging
Drug · Device
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 19, 2015 · Synced Oct 21, 2026, 5:21 PM EDT
Completed Phase 3 Interventional Results available

A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC)

NCT03412773
View directory record Official record
Conditions
Hepatocellular Carcinoma (HCC)
Interventions
Tislelizumab, Sorafenib
Drug
Lead sponsor
BeiGene
Industry
Eligibility
18 Years and older
Enrollment
684 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
9
States / cities
Fullerton, California • Los Angeles, California • Orange, California + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Oct 21, 2026, 5:21 PM EDT
Completed Phase 2 Interventional Results available

CTLA-4 /PD-L1 Blockade Following Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC (Hepatocellular Carcinoma) Using Durvalumab and Tremelimumab

NCT03638141
View directory record Official record
Conditions
Intermediate Stage of Hepatocellular Carcinoma, Hepatocellular Carcinoma
Interventions
Durvalumab, Tremelimumab
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 17, 2025 · Synced Oct 21, 2026, 5:21 PM EDT
Terminated Phase 2 Interventional Results available

Effectiveness and Safety Study of TACE Plus Oral Sorafenib for Unresectable HCC

NCT00576056
View directory record Official record
Conditions
Carcinoma, Hepatocellular
Interventions
Sorafenib, TACE
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 100 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 15, 2017 · Synced Oct 21, 2026, 5:21 PM EDT
Completed Phase 1 Interventional

Stereotactic Body Radiation Therapy and Transarterial Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery

NCT02507765
View directory record Official record
Conditions
Child-Pugh Class A, Child-Pugh Class B, Stage IIIA Hepatocellular Carcinoma, Stage IIIB Hepatocellular Carcinoma, Stage IIIC Hepatocellular Carcinoma, Stage IVA Hepatocellular Carcinoma, Stage IVB Hepatocellular Carcinoma
Interventions
Laboratory Biomarker Analysis, Stereotactic Body Radiation Therapy, Transarterial Chemoembolization
Other · Radiation · Procedure
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 13, 2021 · Synced Oct 21, 2026, 5:21 PM EDT
Completed Not applicable Interventional Results available

Impact of C-arm CT in Patients With HCC Undergoing TACE: Optimal Imaging Guidance

NCT00926536
View directory record Official record
Conditions
Carcinoma, Hepatocellular
Interventions
C-arm CT + DSA as needed, DSA only
Device
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 4, 2016 · Synced Oct 21, 2026, 5:21 PM EDT
Completed Phase 1 Interventional

A First-in-Human Study to Learn About How BAY3630942 is Distributed and Processed Inside the Body When Given After BAY3547922 and How Safe it is in People With Liver Cancer or Other Select Solid Cancers

NCT06345001
View directory record Official record
Conditions
Hepatocellular Carcinoma (HCC), Solid Tumors
Interventions
BAY3630942, BAY3547922
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
4
States / cities
Scottsdale, Arizona • Duarte, California • Los Angeles, California + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2025 · Synced Oct 21, 2026, 5:21 PM EDT
Approved For Marketing No phase listed Expanded access

Himalaya Early Access Program

NCT05345678
View directory record Official record
Conditions
Unresectable Hepatocellular Carcinoma
Interventions
Durvalumab, Tremelimumab
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
4
States / cities
Newark, Delaware • Minneapolis, Minnesota • Reno, Nevada + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2022 · Synced Oct 21, 2026, 5:21 PM EDT
Completed No phase listed Observational

Registration and Fusion of Real-Time Ultrasound With CT for Lesion Localization and Characterization

NCT00586235
View directory record Official record
Conditions
Kidney or Liver Tumors
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 6, 2019 · Synced Oct 21, 2026, 5:21 PM EDT